2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
DNA X, Inc. received a letter on August 28, 2026, from a Nasdaq Hearings Panel saying the company has regained compliance with the $2.5 million stockholders' equity requirement. The company's securities remain subject to delisting if it fails to maintain compliance with all Nasdaq listing rules through November 18, 2026, and it is under a mandatory panel monitor until August 28, 2027. If the company falls below the equity requirement again during that period, it would get no compliance plan or extra time, and its securities could be delisted.
Panel determined the company regained compliance with the $2.5 million stockholders' equity requirement; letter dated August 28, 2026
Securities remain subject to delisting if the company fails to maintain compliance with all Nasdaq rules until November 18, 2026
Mandatory panel monitor runs until August 28, 2027; a new equity deficiency would lead to a delisting determination with no cure period
Microvast Holdings received a Nasdaq notice on August 26, 2026, saying its common stock closed below the $1 minimum bid price for 30 consecutive trading days. The shares remain listed and trading on Nasdaq, and the company has 180 days to regain compliance before any delisting process would begin, which shareholders should watch closely.
Notice received August 26, 2026, under Nasdaq Rule 5450(a)(1) for average closing bid price below $1 over 30 consecutive trading days
Common stock continues to trade on Nasdaq; a non-compliance indicator will appear on NASDAQ.com
Company has 180 days to regain compliance, subject to possible additional time
If not compliant, a delisting notice is expected; an appeal to a Nasdaq Hearings Panel could keep shares listed, but success is not assured
Nutex Health said an unauthorized third party accessed and took information from its servers, including patient, employee, provider, and business data, and has threatened to post it publicly. A class action lawsuit was filed August 27, 2026, and the company says it cannot predict the outcome or estimate the impact on its finances or stock price.
Unauthorized party accessed and exfiltrated data; third party has threatened to post it externally
Purported class action Haley v. Nutex Health, Case No. 4:26-cv-07197, filed August 27, 2026, in the U.S. District Court for the Southern District of Texas
To date, no material impact identified on business operations or financial reporting systems
Company intends to make required notifications, including to impacted patients
BridgeBio entered a voluntary agreement with the U.S. government to expand Medicaid access to Attruby through the GENEROUS Model and lower drug costs. The company says it does not expect to be subject to future pricing mandates, and the specific terms remain confidential.
Agreement expands state Medicaid access to Attruby via the GENEROUS Model; specific terms are confidential
BridgeBio does not expect future pricing mandates; pricing commitments for future medicines are expected to exclude medicines approved exclusively for orphan indications
ForgingBridges copay program is unaffected and can reduce out-of-pocket costs to as little as $0 per month
Pending FDA reviews include BBP-418 (PDUFA November 27, 2026) and encaleret (PDUFA May 7, 2027)
MicroVision received written notice from Nasdaq on August 26, 2026, confirming it had regained compliance with the $1 minimum bid price requirement under Listing Rule 5550(a)(2), and Nasdaq staff concluded the matter is closed. The company had first been notified of noncompliance on January 12, 2026. The filing removes a Nasdaq listing deficiency, but it does not disclose share prices, financial results, or other financial figures.
Nasdaq notice dated August 26, 2026 confirms regained compliance with the $1 minimum bid price rule (Listing Rule 5550(a)(2))
Company was first notified of noncompliance on January 12, 2026
Nasdaq Listing Qualifications staff concluded the matter is now closed; CEO Glen DeVos issued a press release dated August 31, 2026
Cadrenal Therapeutics said that at a Type D meeting with the U.S. Food and Drug Administration held July 28, 2026, the company and the FDA aligned on key aspects of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005 in heparin-induced thrombocytopenia (HIT). The filing says the agreement sets the primary endpoint definition and the use of a placebo control, which the company says clarifies the regulatory path, but it does not disclose financial results, costs, or a trial start date.
Type D meeting with the FDA held July 28, 2026; the company announced the feedback on August 31, 2026.
Primary endpoint measures the proportion of Serotonin Release Assay-positive participants with adjudicated new or worsening composite thromboembolic events through Day 14 or hospital discharge.
The FDA agreed to a placebo control, with standard anticoagulation therapeutics in both the CAD-1005 and placebo arms.
The company states that approximately 50,000 patients in the U.S. have acute HIT each year.
PG&E Corporation will host a webcast and conference call on September 2, 2026, at 8:30 AM Eastern Time to provide an investor update, including its response to Senate Bill 492. The company said it does not believe the bill adequately addresses financing risks created by California's current wildfire liability framework, and that it falls short of providing the long-term durability needed to attract affordable investment.
Investor webcast and conference call set for Wednesday, September 2, 2026, at 8:30 AM Eastern Time
Company says Senate Bill 492 does not adequately address financing risks from California's wildfire liability framework
Replay available by phone at (800) 770-2030 with confirmation code 92587 through September 9, 2026
BioMarin entered a binding term sheet with Ascendis Pharma on August 30, 2026, to settle all pending proceedings over its patent rights covering the C-type natriuretic peptide TransCon CNP (navepegritide, Yuviwel). Ascendis will pay BioMarin royalties on Licensed Product sales, and the parties will dismiss all related litigation with prejudice, including the ITC Section 337 investigation. The filing gives no financial value for the settlement or the royalties beyond the rates, so the effect on BioMarin's results cannot be measured from this filing.
Royalty of 20% of annual net sales in the United States and 18% in the European Union, Brazil and South Korea, running until May 2030
BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to its patents for all current and potential indications, including achondroplasia and hypochondroplasia
Term sheet is binding as of August 30, 2026; parties must sign the full Agreement by September 24, 2026, or the term sheet terms continue to bind
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.